Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial

BMC Gastroenterology

Volumn 12, Issue , 2012, Pages

  Yakoot, Mostafa ^a   Salem, Amel ^b  

^a Green Clinic and Research Centre   (Egypt)

^b Mabarrah Clinics   (Egypt)

Author keywords

Chronic hcv; Cyanobacteria; Safety and efficacy; Silymarin; Spirulina platensis

Indexed keywords

ALANINE AMINOTRANSFERASE; SILYMARIN; SPIRULINA EXTRACT; ANTIVIRUS AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARIZONA SEXUAL EXPERIENCE SCALE SCORE; ARTICLE; CHRONIC LIVER DISEASE QUESTIONNAIRE SCORES; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPIRULINA PLATENSIS; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ENZYMOLOGY; QUESTIONNAIRE; SPIRULINA; VIRUS LOAD;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DIETARY SUPPLEMENTS; HEPATITIS C, CHRONIC; HUMANS; PILOT PROJECTS; QUESTIONNAIRES; SILYMARIN; SPIRULINA; VIRAL LOAD;

EID: 84859632884     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-12-32     Document Type: Article

References (45)

1. World Health Organization Hepatitis C. Factsheet No 164 (updated Oct 2000). (accessed 3 Feb 2008), World Health Organization., http://www.who.int/mediacentre/factsheets/en/
2. Patel K, Muir AJ, McHutchison JG. Diagnosis and treatment of chronic hepatitis C infection. BMJ 2006, 332(7548):1013-7. 10.1136/bmj.332.7548.1013, 1450048, 16644828.
3. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease Center for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1998, 47:1-39. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease.
4. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011, 31(2):61-80.
5. Hepatitis C. Global prevalence. Wkly Epidemiol Rec 1997, 72:341-344.
6. Management of hepatitis C NIH Consens State Sci Statements. 2002, 19(3):1-46. Management of hepatitis C.
7. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naïve patients. Viral Hepat 1999, 8:4862.
8. Camma C, Licata A, Cabibbo G, Latteri F, Craxi A. Treatment of hepatitis C: critical appraisal of the evidence. Expert Opin Pharmacother 2005, 6:399-408. 10.1517/14656566.6.3.399, 15794731.
9. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006, 55:1350-1359. 10.1136/gut.2005.076646, 1860034, 16905701.
10. Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008, 47:1371-83. 10.1002/hep.22127, 18240152.
11. Zeuzem S, Hultcrantz R, Bourliere M. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004, 40:993-999. 10.1016/S0168-8278(04)00060-1, 15158341.
12. Moucari R, Ripault MP, Oules V, et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol 2007, 46:596-604. 10.1016/j.jhep.2006.10.016, 17218037.
13. Koretz RL. Interferon in wonderland. Gastroenterology 1998, 115:1027-29.
14. Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Dig Liver Dis 2007, 39(4):293-304. 10.1016/j.dld.2006.11.004, 17331820.
15. Batey RG, Bensoussan A, Fan YY, Bollipo S, Hossain MA. Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 1998, 3(3):244-7.
16. Wu C, et al. Thirty-three patients with hepatitis C treated by chinese traditional medicine syndrome differentiation. Chinese Journal of Integrated Traditional and Western Medicine for Liver Diseases 1994, 4:44-45.
17. Cohen MR. Herbal and complementary and alternative medicine therapies for liver disease. A focus on Chinese traditional medicine in hepatitis C virus. Clin Liver Dis 2001, 5(2):461-78. vii, 10.1016/S1089-3261(05)70174-4, 11385972.
18. Suzuki H, et al. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis double blind trial. Journal of Asian Medicine 1984, 26:423-38.
19. Kay RA. Microalgae as food and supplement. Critical Rev Food Sci Nutr 1991, 555-73. CRC Press, USA.
20. Karkos PD, Leong SC, Karkos CD, Sivaji N, Assimakopoulos DA. Spirulina in Clinical Practice: Evidence-Based Human Applications. Evid Based Complement Alternat Med 2008, doi:10.1093/ecam/nen058. PubMed Central PMCID: PMC3136577.
21. Salazar M, Chamorro GA, Salazar S, Steele CE. Effect of Spirulina maxima consumption on reproduction and peri- and postnatal development in rats. Food Chem Toxicol 1996, 34(4):353-359. 10.1016/0278-6915(96)00000-2, 8641661.
22. Chamorro G, Salazar S, Castillo L. Reproductive and peri- postnatal evaluation of Spirulina maxima in mice. J Appl Phycol 1997, 9:107-12.
23. Salazar M, Martinez E, Madrigal E, Ruiz LE, Chamorro GA. Subchronic toxicity study in mice fed Spirulina. J Ethnopharmacol 1998, 62:235-41. 10.1016/S0378-8741(98)00080-4, 9849634.
24. Belay A. The potential application of Spirulina (Arthrospira) as a nutritional and therapeutic supplement in Health management. JANA 2002, 5:27-48.
25. Hirahashi T, Matsumoto M, Hazeki K, Saeki Y, Ui M, Seya T. Activation of the human innate immune system by spirulina: augmentation of interferon production and NK cytotoxicity by oral administration of hot water extract of Spirulina platensis. Int Immunopharmacol 2002, 2:423-34. 10.1016/S1567-5769(01)00166-7, 11962722.
26. Pugh N, Ross SA, ElSohly HN, et al. Isolation of three high molecular weight polysaccharide preparations with potent immunostimulatory activity from Spirulina platensis, aphanizomenon flos-aquae and Chlorella pyrenoidosa. Planta Med 2001, 8:737-42.
27. Blinkova LP, Gorobets OB, Baturo AP. Biological activity of Spirulina. Zh Mikrobiol Epidemiol Immunobiol 2001, 2:114-8.
28. Hayashi O, Katoh T, Okuwaki Y. Enhancement of antibody production in mice by dietary Spirulina platensis. J Nutr Sci Vitaminol 1994, 40(5):431-41. 10.3177/jnsv.40.431, 7891204.
29. Hernandez-Corona A, Nieves I, Meckes M. Antiviral activity of spirulina maxima against herpes simplex virus type 2. Antiviral Res 2002, 56(3):279-85. 10.1016/S0166-3542(02)00132-8, 12406511.
30. Schaeffer DJ, Krylov VS. Anti-HIV activity of extracts and compounds from algae and cyanobacteria. Ecotoxicol En Spirulina Saf 2000, 45(3):208-27.
31. Hayashi T. Studies on evaluation of natural products for antiviral effects and their applications. Yakugaku Zasshi 2008, 128(1):61-79. 10.1248/yakushi.128.61, 18176057.
32. Hayashi K, Hayashi T, Kojima I. A natural sulfated polysaccharide, calcium spirulan, isolated from Spirulina platensis: in vitro and ex vivo evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities. AIDS Res Hum Retroviruses 1996, 12(15):1463-71. 10.1089/aid.1996.12.1463, 8893054.
33. Boyd MR, Gustafson KR, McMahon JB, et al. Antimicrob. Agents Chemother 1997, 41:1521-30.
34. Dey B, Lerner D, Lusso P, et al. J Virol 2000, 74:4562-69. 10.1128/JVI.74.10.4562-4569.2000, 111976, 10775592.
35. Esser MT, Mori T, Mondor I, et al. J Virol 1999, 73:4360-71. 104217, 10196334.
36. Huskens D, Férir G, Vermeire K, et al. Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile. J Biol Chem 2010, 285(32):24845-54. 10.1074/jbc.M110.128546, 2915720, 20507987.
37. Kehr JC, Zilliges Y, Springer A, et al. A mannan binding lectin is involved in cell-cell attachment in a toxic strain of microcystis aeruginosa. Mol Microbiol 2006, 59(3):893-906. 10.1111/j.1365-2958.2005.05001.x, 16420359.
38. Helle F, Wychowski C, Vu-Dac N, et al. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem 2006, 281(35):25177-83. 10.1074/jbc.M602431200, 16809348.
39. Balzarini J. Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?. Antivir Chem Chemother 2007, 18(1):1-11.
40. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999, 45:295-300. 10.1136/gut.45.2.295, 1727607, 10403745.
41. Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001, 96:579-583. 10.1111/j.1572-0241.2001.03537.x, 11232711.
42. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, Manber R. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000, 26(1):25-40. 10.1080/009262300278623, 10693114.
43. Bǎicuş C, Tǎnǎsescu C. Chronic viral hepatitis, the treatment with spiruline for one month has no effect on the aminotransferases. Rom J Intern Med 2002, 40(1-4):89-94.
44. Danoff A, Khan O, Wan DW, Hurst L, Cohen D, Tenner CT, Bini EJ. Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life. Am J Gastroenterol 2006, 101(6):1235-43. 10.1111/j.1572-0241.2006.00544.x, 16771944.
45. Soykan A, Boztaş H, Idilman R, Ozel ET, Tüzün AE, Ozden A, Ozden A, Kumbasar H. Sexual dysfunctions in HCV patients and its correlations with psychological and biological variables. Int J Impot Res 2005, 17(2):175-9. 10.1038/sj.ijir.3901267, 15510190.